New psoriasis drug tracked for 5 years in Real-World german study
NCT ID NCT06104644
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 550 adults with moderate-to-severe plaque psoriasis who are starting deucravacitinib in routine German clinics. Over 5 years, researchers will measure how well the drug clears skin and improves quality of life. The goal is to see how the treatment works outside of controlled trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatologische Spezial- und Schwerpunktpraxis Selters
Selters, Rhineland-Palatinate, Germany
-
Local Institution - 0001
Selters, 56242, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial
- Psoriasis drug may be safe for patients with fatty liver
- New cream shows promise for clearing psoriasis in chinese patients
- Could a simple skincare routine soothe psoriasis Flare-Ups?
- New psoriasis cream shows early promise in small trial
- New biologic drug netakimab tested in kids with psoriasis